-
Je něco špatně v tomto záznamu ?
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
NC. Cross, HE. White, D. Colomer, H. Ehrencrona, L. Foroni, E. Gottardi, T. Lange, T. Lion, K. Machova Polakova, S. Dulucq, G. Martinelli, E. Oppliger Leibundgut, N. Pallisgaard, G. Barbany, T. Sacha, R. Talmaci, B. Izzo, G. Saglio, F. Pane, MC....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 1997-01-01 do 2015-11-30
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
PubMed
25652737
DOI
10.1038/leu.2015.29
Knihovny.cz E-zdroje
- MeSH
- bcr-abl fúzní proteiny genetika MeSH
- chronická myeloidní leukemie farmakoterapie metabolismus MeSH
- genetická variace MeSH
- kalibrace MeSH
- lidé MeSH
- limita detekce MeSH
- polymerázová řetězová reakce MeSH
- regulace genové exprese u leukemie * MeSH
- reprodukovatelnost výsledků MeSH
- stanovení celkové genové exprese MeSH
- tyrosinkinasy antagonisté a inhibitory MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
3 Medizinische Klinik Universitätsmedizin Mannheim Mannheim Germany
Abteilung für Hämatologie und internistische Onkologie Universität Leipzig Leipzig Germany
Abteilung Hämatologie Onkologie Klinik für Innere Medizin 2 Universitätsklinikum Jena Jena Germany
Children's Cancer Research Institute LabDia Labordiagnostik and Medical University Vienna Austria
Department of Clinical and Biological Science University of Turin Turin Italy
Department of Clinical Genetics Laboratory Medicine Lund University Lund Sweden
Department of Clinical Medicine and Surgery University 'Federico II' of Naples Naples Italy
Department of Experimental Diagnostic and Specialty Medicine University of Bologna Bologna Italy
Hematology Department Jagiellonian University Krakow Poland
Hematopathology Unit Hospital Clinic IDIBAPS Barcelona Spain
Imperial Molecular Pathology Laboratory Centre for Haematology Imperial College London London UK
Institute of Hematology and Blood Transfusion Prague Czech Republic
Klinisk Biokemi Vejle Sygehus Vejle Denmark
Molecular Diagnostics Laboratory Department of Hematology University Hospital Bern Bern Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031476
- 003
- CZ-PrNML
- 005
- 20151013125323.0
- 007
- ta
- 008
- 151005s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/leu.2015.29 $2 doi
- 035 __
- $a (PubMed)25652737
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cross, N C P $u 1] Faculty of Medicine, University of Southampton, Southampton, UK [2] National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK.
- 245 10
- $a Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia / $c NC. Cross, HE. White, D. Colomer, H. Ehrencrona, L. Foroni, E. Gottardi, T. Lange, T. Lion, K. Machova Polakova, S. Dulucq, G. Martinelli, E. Oppliger Leibundgut, N. Pallisgaard, G. Barbany, T. Sacha, R. Talmaci, B. Izzo, G. Saglio, F. Pane, MC. Müller, A. Hochhaus,
- 520 9_
- $a Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
- 650 _2
- $a kalibrace $7 D002138
- 650 _2
- $a bcr-abl fúzní proteiny $x genetika $7 D016044
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 12
- $a regulace genové exprese u leukemie $7 D015973
- 650 _2
- $a genetická variace $7 D014644
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická myeloidní leukemie $x farmakoterapie $x metabolismus $7 D015464
- 650 _2
- $a limita detekce $7 D057230
- 650 _2
- $a polymerázová řetězová reakce $7 D016133
- 650 _2
- $a tyrosinkinasy $x antagonisté a inhibitory $7 D011505
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a White, H E $u 1] Faculty of Medicine, University of Southampton, Southampton, UK [2] National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK.
- 700 1_
- $a Colomer, D $u Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain.
- 700 1_
- $a Ehrencrona, H $u Department of Clinical Genetics, Laboratory Medicine, Lund University, Lund, Sweden.
- 700 1_
- $a Foroni, L $u Imperial Molecular Pathology Laboratory, Centre for Haematology, Imperial College London, London, UK.
- 700 1_
- $a Gottardi, E $u Department of Clinical and Biological Science, University of Turin, Turin, Italy.
- 700 1_
- $a Lange, T $u Abteilung für Hämatologie und internistische Onkologie, Universität Leipzig, Leipzig, Germany.
- 700 1_
- $a Lion, T $u Children's Cancer Research Institute/LabDia Labordiagnostik and Medical University, Vienna, Austria.
- 700 1_
- $a Machova Polakova, K $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Dulucq, S $u Laboratoire Hematologie, CHU Bordeaux, Hematopoiese Leucemique et Cibles Therapeutiques, INSERM U1035, Université Bordeaux, Bordeaux, France.
- 700 1_
- $a Martinelli, G $u Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
- 700 1_
- $a Oppliger Leibundgut, E $u Molecular Diagnostics Laboratory, Department of Hematology, University Hospital Bern, Bern, Switzerland.
- 700 1_
- $a Pallisgaard, N $u Klinisk Biokemi, Vejle Sygehus, Vejle, Denmark.
- 700 1_
- $a Barbany, G $u Department of Molecular Medicine and Surgery, Clinical Genetics, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Sacha, T $u Hematology Department, Jagiellonian University, Krakow, Poland.
- 700 1_
- $a Talmaci, R $u Hematology Department - Fundeni Clinical Institute, University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania.
- 700 1_
- $a Izzo, B $u Department of Clinical Medicine and Surgery, University 'Federico II' of Naples, Naples, Italy.
- 700 1_
- $a Saglio, G $u Department of Clinical and Biological Science, University of Turin, Turin, Italy.
- 700 1_
- $a Pane, F $u 1] Department of Clinical Medicine and Surgery, University 'Federico II' of Naples, Naples, Italy [2] CEINGE - Biotecnologie Avanzate, Naples, Italy.
- 700 1_
- $a Müller, M C $u III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany.
- 700 1_
- $a Hochhaus, A $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 29, č. 5 (2015), s. 999-1003
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25652737 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20151013125512 $b ABA008
- 999 __
- $a ok $b bmc $g 1092352 $s 914602
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 29 $c 5 $d 999-1003 $e 20150205 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20151005
